Pharsight

Collegium Pharm Inc patents expiration

1. Nucynta patents expiration

NUCYNTA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE39593 COLLEGIUM PHARM INC 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
Aug, 2022

(1 year, 8 months ago)

US7994364 COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Jun, 2025

(1 year, 2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6071970 COLLEGIUM PHARM INC Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
Jun, 2017

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 03, 2026
New Chemical Entity Exclusivity(NCE) Nov 20, 2013

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

NCE-1 date: 20 November, 2012

Market Authorisation Date: 15 October, 2012

Treatment: Relief of moderate to severe acute pain; Management of moderate to severe acute pain

Dosage: SOLUTION;ORAL; TABLET;ORAL

How can I launch a generic of NUCYNTA before it's drug patent expiration?
More Information on Dosage

NUCYNTA family patents

Family Patents

2. Nucynta Er patents expiration

NUCYNTA ER's oppositions filed in EPO
NUCYNTA ER Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE39593 COLLEGIUM PHARM INC 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
Aug, 2022

(1 year, 8 months ago)

US7994364 COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Jun, 2025

(1 year, 2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6071970 COLLEGIUM PHARM INC Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
Jun, 2017

(6 years ago)

US11007156 COLLEGIUM PHARM INC Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
Oct, 2022

(1 year, 5 months ago)

US8075872 COLLEGIUM PHARM INC Abuse-proofed dosage form
Nov, 2023

(4 months ago)

US8420056 COLLEGIUM PHARM INC Abuse-proofed dosage form
Nov, 2023

(4 months ago)

US8309060 COLLEGIUM PHARM INC Abuse-proofed dosage form
Nov, 2023

(4 months ago)

US8114383 COLLEGIUM PHARM INC Abuse-proofed dosage form
Oct, 2024

(5 months from now)

US11344512 COLLEGIUM PHARM INC Titration of tapentadol
Apr, 2028

(4 years from now)

US8536130 COLLEGIUM PHARM INC Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain
Sep, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Aug 25, 2014
New Chemical Entity Exclusivity(NCE) Nov 20, 2013
New Indication(I-656) Aug 28, 2015

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

NCE-1 date: 20 November, 2012

Market Authorisation Date: 25 August, 2011

Treatment: Relief of moderate to severe chronic pain; A method of titrating an opioid to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatme...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of NUCYNTA ER before it's drug patent expiration?
More Information on Dosage

NUCYNTA ER family patents

Family Patents

3. Xtampza Er patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10525053 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opioids and other drugs
Jul, 2023

(9 months ago)

US9248195 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opioids and other drugs
Jul, 2023

(9 months ago)

US10525052 COLLEGIUM PHARM INC Abuse-deterrent drug formulations
Jul, 2023

(9 months ago)

US8840928 COLLEGIUM PHARM INC Tamper-resistant pharmaceutical compositions of opioids and other drugs
Jul, 2023

(9 months ago)

US9763883 COLLEGIUM PHARM INC Abuse-deterrent drug formulations
Jul, 2023

(9 months ago)

US9592200 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opioids and other drugs
Jul, 2023

(9 months ago)

US9044398 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opiods and other drugs
Jul, 2023

(9 months ago)

US8557291 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opioids and other drugs
Mar, 2025

(10 months from now)

US7399488 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opiods and other drugs
Mar, 2025

(11 months from now)

US7771707 COLLEGIUM PHARM INC Abuse-deterrent drug formulations
Mar, 2025

(11 months from now)

US8449909 COLLEGIUM PHARM INC Abuse-deterrent drug formulations
Mar, 2025

(11 months from now)

US8758813 COLLEGIUM PHARM INC Abuse-deterrent drug formulations
Jun, 2025

(1 year, 1 month from now)

US10668060 COLLEGIUM PHARM INC Tamper-resistant pharmaceutical compositions of opioids and other drugs
Dec, 2030

(6 years from now)

US9682075 COLLEGIUM PHARM INC Tamper-resistant pharmaceutical compositions of opioids and other drugs
Dec, 2030

(6 years from now)

US10004729 COLLEGIUM PHARM INC Tamper-resistant pharmaceutical compositions of opioids and other drugs
Dec, 2030

(6 years from now)

US9737530 COLLEGIUM PHARM INC Process of making stable abuse-deterrent oral formulations
Sep, 2036

(12 years from now)

US9968598 COLLEGIUM PHARM INC Process of making stable abuse-deterrent oral formulations
Sep, 2036

(12 years from now)

US10188644 COLLEGIUM PHARM INC Process of making stable abuse-deterrent oral formulations
Sep, 2036

(12 years from now)

US10646485 COLLEGIUM PHARM INC Process of making stable abuse-deterrent oral formulations
Sep, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 26, 2019

Drugs and Companies using OXYCODONE ingredient

Market Authorisation Date: 26 April, 2016

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of XTAMPZA ER before it's drug patent expiration?
More Information on Dosage

XTAMPZA ER family patents

Family Patents